HRP20130114T4 - Farmaceutski oblik s brzim oslobađanjem sinakalcet hci - Google Patents

Farmaceutski oblik s brzim oslobađanjem sinakalcet hci Download PDF

Info

Publication number
HRP20130114T4
HRP20130114T4 HRP20130114TT HRP20130114T HRP20130114T4 HR P20130114 T4 HRP20130114 T4 HR P20130114T4 HR P20130114T T HRP20130114T T HR P20130114TT HR P20130114 T HRP20130114 T HR P20130114T HR P20130114 T4 HRP20130114 T4 HR P20130114T4
Authority
HR
Croatia
Prior art keywords
mixture
weight
mixture according
total mass
amount
Prior art date
Application number
HRP20130114TT
Other languages
English (en)
Croatian (hr)
Inventor
Francisco J. Alvarez
Glen Gary Lawrence
Hung-Ren Lin
Tzuchi R. Ju
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130114(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HRP20130114T1 publication Critical patent/HRP20130114T1/hr
Publication of HRP20130114T4 publication Critical patent/HRP20130114T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20130114TT 2003-09-12 2004-09-10 Farmaceutski oblik s brzim oslobađanjem sinakalcet hci HRP20130114T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound
EP04781429.8A EP1663182B2 (en) 2003-09-12 2004-09-10 RAPID DISSOLUTION FORMULATION OF CINACALCET HCl

Publications (2)

Publication Number Publication Date
HRP20130114T1 HRP20130114T1 (xx) 2013-03-31
HRP20130114T4 true HRP20130114T4 (hr) 2019-12-27

Family

ID=34434844

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130114TT HRP20130114T4 (hr) 2003-09-12 2004-09-10 Farmaceutski oblik s brzim oslobađanjem sinakalcet hci

Country Status (30)

Country Link
US (7) US7829595B2 (enExample)
EP (8) EP2821067B1 (enExample)
JP (3) JP5026077B2 (enExample)
KR (1) KR101332058B1 (enExample)
CN (1) CN1946382B (enExample)
AR (1) AR045637A1 (enExample)
AU (1) AU2004279318C1 (enExample)
BR (2) BRPI0414254B8 (enExample)
CA (1) CA2536487C (enExample)
CY (5) CY1119609T1 (enExample)
DE (1) DE19164145T1 (enExample)
DK (6) DK3260117T3 (enExample)
EA (1) EA013425B1 (enExample)
ES (7) ES2655435T3 (enExample)
HR (1) HRP20130114T4 (enExample)
HU (5) HUE044822T2 (enExample)
IL (1) IL173737A (enExample)
IS (1) IS3027B (enExample)
MX (1) MXPA06002616A (enExample)
MY (1) MY142046A (enExample)
NO (1) NO335739B1 (enExample)
NZ (1) NZ545498A (enExample)
PL (6) PL3395338T3 (enExample)
PT (6) PT3395338T (enExample)
SG (1) SG146608A1 (enExample)
SI (6) SI3395340T1 (enExample)
TR (4) TR201910447T4 (enExample)
TW (1) TWI344363B (enExample)
WO (1) WO2005034928A1 (enExample)
ZA (1) ZA200602710B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
ES2332016T3 (es) * 2005-05-16 2010-01-22 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de hidrocloruro de cinacalcet.
EP1883618B1 (en) * 2005-05-23 2009-10-14 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
JP2008507567A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
CN101184489B (zh) 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
ES2400693T3 (es) * 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
TW200811082A (en) * 2006-04-27 2008-03-01 Teva Pharma Process for the preparation of cinacalcet base
WO2007127445A2 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
US20110189241A1 (en) * 2008-05-05 2011-08-04 Medichem, S.A. Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2334284B1 (de) * 2008-09-25 2012-08-08 Ratiopharm GmbH Kompaktiertes cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
RS60203B1 (sr) * 2010-11-23 2020-06-30 Amgen Inc Pedijatrijska formulacija
CN103228629A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 作为CaSR活性化合物的被取代的环戊基-氮杂苯类
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069420A2 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) * 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
BR112015014430B1 (pt) 2012-12-21 2022-08-30 Synthon B.V. Composição em comprimido
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3013324A1 (en) 2013-06-26 2016-05-04 Jubilant Generics Limited Disintegrant free composition of cinacalcet
EP3116487A1 (en) * 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
WO2017182237A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
US11413295B2 (en) 2016-03-31 2022-08-16 Intercept Pharmaceuticals, Inc. Oral preparation of obeticholic acid
EP3668493A4 (en) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS WITH CINACALCET HYDROCHLORIDE AND ONE OR MORE BINDERS
US20210030671A1 (en) 2018-03-30 2021-02-04 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
BR112022017133A2 (pt) * 2020-02-29 2022-10-11 Kempharm Inc Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
EP0373417A1 (en) 1988-11-30 1990-06-20 Schering Corporation Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE312347T1 (de) 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
ATE267009T1 (de) 1993-02-23 2004-06-15 Brigham & Womens Hospital Calciumrezeptoraktive moleküle
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
HU228150B1 (en) * 1994-10-21 2012-12-28 Nps Pharma Inc Calcium receptor-active compounds, medicaments comprising them, and the use of said medicaments
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
EP0907631B1 (en) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AU734710B2 (en) 1996-07-08 2001-06-21 Kyowa Hakko Kirin Co., Ltd. Calcium receptor active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
DE69901938T3 (de) 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
JP2002527414A (ja) 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
NZ511850A (en) * 1998-11-23 2003-11-28 Monsanto Co Highly concentrated aqueous glyphosate compositions
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (enExample) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003000294A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2003238670A1 (en) 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
KR20070043043A (ko) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2717906C (en) 2008-03-11 2022-07-05 Jamu Alford System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
US20050147669A1 (en) 2005-07-07
NO20061640L (no) 2006-06-12
DK3395340T3 (da) 2019-07-15
TW200518743A (en) 2005-06-16
EP3395340B1 (en) 2019-04-17
DK1663182T4 (da) 2020-02-17
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
CA2536487C (en) 2011-10-25
US20160338975A1 (en) 2016-11-24
ES2735216T3 (es) 2019-12-17
ES2735226T3 (es) 2019-12-17
HUE043958T2 (hu) 2019-09-30
TR201910447T4 (tr) 2019-08-21
PT1663182E (pt) 2013-03-14
IL173737A (en) 2012-04-30
ZA200602710B (en) 2007-04-25
EP2316442A1 (en) 2011-05-04
ES2655435T3 (es) 2018-02-20
JP5849015B2 (ja) 2016-01-27
US20210052518A1 (en) 2021-02-25
TR201910180T4 (tr) 2019-07-22
HUE045411T2 (hu) 2019-12-30
IS3027B (is) 2021-03-15
MY142046A (en) 2010-08-30
ES2401769T3 (es) 2013-04-24
US20190117592A1 (en) 2019-04-25
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
BR122018013029B1 (pt) 2022-04-12
SG146608A1 (en) 2008-10-30
US9375405B2 (en) 2016-06-28
US7829595B2 (en) 2010-11-09
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
KR20070017460A (ko) 2007-02-12
DK3260117T3 (da) 2019-07-01
AU2004279318B2 (en) 2010-02-25
BRPI0414254B1 (pt) 2021-03-02
EP3578175B1 (en) 2022-11-30
ES2734057T3 (es) 2019-12-04
AU2004279318C1 (en) 2020-06-25
TR201909267T4 (tr) 2019-07-22
HUE035596T2 (en) 2018-05-28
CN1946382B (zh) 2010-12-08
US20200222340A1 (en) 2020-07-16
SI2821067T1 (en) 2018-03-30
ES2401769T5 (es) 2020-07-01
ES2812198T1 (es) 2021-03-16
CY1121820T1 (el) 2020-07-31
JP5940120B2 (ja) 2016-06-29
CY1121814T1 (el) 2020-07-31
PT3395339T (pt) 2019-07-15
SI1663182T1 (sl) 2013-05-31
PT3260117T (pt) 2019-07-04
EP3395340B8 (en) 2019-12-11
PT3395338T (pt) 2019-07-23
PL2821067T3 (pl) 2018-02-28
EP1663182A1 (en) 2006-06-07
PL1663182T3 (pl) 2013-06-28
SI3395340T1 (sl) 2019-08-30
PL3260117T3 (pl) 2019-10-31
SI3395338T1 (sl) 2019-08-30
EP3395338B1 (en) 2019-05-01
DK3395338T3 (da) 2019-07-22
PL3395339T3 (pl) 2019-09-30
SI1663182T2 (sl) 2020-02-28
EP3395339B8 (en) 2019-12-11
EA200600566A1 (ru) 2006-08-25
BRPI0414254B8 (pt) 2021-05-25
TR201910177T4 (tr) 2019-08-21
EP3395339B1 (en) 2019-04-17
IS8324A (is) 2006-02-23
CA2536487A1 (en) 2005-04-21
CN1946382A (zh) 2007-04-11
EP3260117B8 (en) 2019-11-27
US20110136915A1 (en) 2011-06-09
DK1663182T3 (da) 2013-04-15
EP3395338A1 (en) 2018-10-31
US20180243238A1 (en) 2018-08-30
CY1121812T1 (el) 2020-07-31
EA013425B1 (ru) 2010-04-30
IL173737A0 (en) 2006-07-05
NZ545498A (en) 2010-04-30
JP2007505108A (ja) 2007-03-08
EP3260117B1 (en) 2019-04-17
EP3395339A1 (en) 2018-10-31
EP2821067B1 (en) 2017-10-25
ES2737348T3 (es) 2020-01-13
EP3260117A1 (en) 2017-12-27
EP1663182B2 (en) 2019-11-20
DK3395339T3 (da) 2019-07-22
PT2821067T (pt) 2017-12-01
CY1119609T1 (el) 2018-04-04
SI3260117T1 (sl) 2019-08-30
AU2004279318A1 (en) 2005-04-21
DE19164145T1 (de) 2021-04-29
HUE044822T2 (hu) 2019-11-28
NO335739B1 (no) 2015-02-02
HUE044279T2 (hu) 2019-10-28
BRPI0414254A (pt) 2006-11-07
CY1122259T1 (el) 2020-11-25
PL1663182T5 (pl) 2020-07-27
AR045637A1 (es) 2005-11-02
SI3395339T1 (sl) 2019-08-30
TWI344363B (en) 2011-07-01
PT3395340T (pt) 2019-07-15
PL3395338T3 (pl) 2019-10-31
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
PL3395340T3 (pl) 2019-10-31
EP2821067A1 (en) 2015-01-07
JP2012197280A (ja) 2012-10-18
JP5026077B2 (ja) 2012-09-12
WO2005034928A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
HRP20130114T4 (hr) Farmaceutski oblik s brzim oslobađanjem sinakalcet hci
HRP20040996A2 (en) High drug load tablet
KR20080075535A (ko) 수-불용성 무기 인산염 결합제를 포함한 과립성 물질
HRP20161329T1 (hr) Oralni oblici doziranja koji sadrže likarbazepin acetat
HRP20110294T1 (hr) Smjese u obliku tablete koje sadržavaju atazanavir
EP4041199A1 (en) Essentially sodium-free effervescent solid pharmaceutical compositions
HRP20161470T1 (hr) Smjese flurbiprofena s kontroliranim otpuštanjem i mišićnog relaksanta
ES2290181T3 (es) Composiciones farmaceuticas.
KR20130115101A (ko) 제약 산업에서 규조토의 용도
BR0308305A (pt) Fórmulas dosadas de liberação controlada
US20060222703A1 (en) Pharmaceutical composition and preparation method thereof
BRPI0520610A2 (pt) formulação de comprimido de medicamento para alìvio de dor
TW201043640A (en) Method to stabilize a dietary supplement to facilitate joint health in humans
EP0689434B1 (en) Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof
AU2014295098A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
TWI630911B (zh) 包含異菸鹼醯胺（ｉｓｏｎｉａｚｉｄ）顆粒及利福噴丁（ｒｉｆａｐｅｎｔｉｎｅ）顆粒之可分散錠劑型態的抗肺結核穩定醫藥組合物及其製備方法
JP2021073275A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
ES2373492T3 (es) Composición farmacéutica con ingrediente activo atorvastatina.
Jain et al. Development and evaluation of sustained release matrix tablet of lamivudine
Sipos et al. Comparative study on the rheological properties and tablettability of various APIs and their composites with titanate nanotubes
Sarangi et al. Formulation Development and evaluation of Bilayer tablets containing Paracetamol SR and Tizanidine
Patil et al. Development and evaluation of time controlled pulsatile release Lisinopril tablets
RU2192848C1 (ru) Противорвотное средство
Srilakshmi et al. FORMULATION AND EVALUATION OF MATRIX TABLETS OF METFORMIN HYDROCHLORIDE
Krishnamoorthy et al. FORMULATION AND EVALUATION OF BI-LAYERED TABLET OF DIVALPROEX SODIUM